NCT02997189View on ClinicalTrials.gov

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

September 26, 2017

Study Completion Date

September 26, 2017

Conditions
Cisplatin Induced Hearing Loss
Interventions
DRUG

OTO-104

12 mg dexamethasone administered intratympanically

Trial Locations (1)

92121

Contact Otonomy call center for trial locations, San Diego

Sponsors

Lead Sponsor

Otonomy, Inc.
All Listed Sponsors
lead

Otonomy, Inc.

INDUSTRY